January 11, 2023

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition WALTHAM, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) — […]

Nikkiso Clean Energy & Industrial Gases Group Announces their First On-Site FAT Testing at their Marine Facility in Busan, Korea

TEMECULA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) — Nikkiso Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is proud to announce its first on-site FAT testing at their new Marine facility in Busan, Korea. This accomplishment exemplifies their commitment to and support of the growth […]

Security situation in Sahel has worsened: UN envoy

UNITED NATIONS— The security situation has deteriorated in large parts of West Africa and the Sahel despite efforts by national security forces and international partners, said a UN envoy.In the past six months, more than 10,000 schools across the Sahe…

1 child or youth died every 4.4 seconds in 2021: UN

UNITED NATIONS— An estimated 5 million children died before their fifth birthday and another 2.1 million children and youth aged between 5 and 24 years lost their lives in 2021, according to the latest estimates released by the UN Inter-agency Group fo…

Recent Posts